



US008399514B2

(12) **United States Patent**
Lukashev et al.

(10) **Patent No.:** **US 8,399,514 B2**
(45) **Date of Patent:** **Mar. 19, 2013**

(54) **TREATMENT FOR MULTIPLE SCLEROSIS**
(75) Inventors: **Matvey E. Lukashev**, Tewksbury, MA (US); **Gilmore O'Neill**, Medford, MA (US)
(73) Assignee: **Biogen Idec MA Inc.**, Cambridge, MA (US)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
(21) Appl. No.: **13/372,426**

7,803,840 B2 9/2010 Joshi et al.
7,871,977 B2 1/2011 Rischer et al.
7,906,659 B2 3/2011 Joshi et al.
7,915,310 B2 3/2011 Joshi et al.
8,067,467 B2 11/2011 Joshi et al.
2003/0176365 A1 9/2003 Blass
2004/0054001 A1 3/2004 Joshi et al.
2005/0245612 A1 11/2005 Blass
2007/0027076 A1 2/2007 Joshi et al.
2008/0089861 A1 4/2008 Went et al.
2008/0233185 A1 9/2008 Joshi et al.
2010/0130607 A1 5/2010 Gold
2011/0112196 A1 5/2011 Lukashev
2011/0124615 A1 5/2011 Joshi et al.
2011/0293711 A1 12/2011 Joshi et al.
2012/0165404 A1 6/2012 Lukashev

FOREIGN PATENT DOCUMENTS

(22) Filed: **Feb. 13, 2012**
(65) **Prior Publication Data**
US 2012/0196931 A1 Aug. 2, 2012

CA 2248955 A1 5/1997
CN 1125141 A 6/1996
DE 25 30 372 A1 1/1977
DE 26 21 214 A1 11/1977
DE 28 40 498 B1 8/1979
DE 38 34 794 A1 4/1990
DE 197 21 099 A1 11/1998
EP 0 188 749 A2 7/1986
EP 0 312 697 A2 4/1989
EP 0 518 388 A2 12/1992
EP 0 793 966 A1 9/1997
EP 0 852 233 A1 7/1998
GB 2 291 422 A 1/1996
JP 54-80439 A 6/1979
JP 6-345644 A 12/1994
JP 8-99906 A 4/1996
JP 9-221428 A 8/1997
RU 2 189 813 C1 9/2002
WO WO 89/01930 A1 3/1989
WO WO 94/28883 A1 12/1994
WO WO 95/25102 A1 9/1995
WO WO 96/01122 A1 1/1996
WO WO 96/08970 A1 3/1996
WO WO 97/09984 A1 3/1997
WO WO 97/13504 A1 4/1997

Related U.S. Application Data

(63) Continuation of application No. 12/526,296, filed as application No. PCT/US2008/001602 on Feb. 7, 2008, now abandoned.
(60) Provisional application No. 60/888,921, filed on Feb. 8, 2007.
(51) **Int. Cl.**
A61K 31/22 (2006.01)
(52) **U.S. Cl.** **514/549**
(58) **Field of Classification Search** None
See application file for complete search history.

(Continued)

(56) **References Cited**
U.S. PATENT DOCUMENTS

4,515,974 A 5/1985 Zecher et al.
4,746,668 A 5/1988 Sato et al.
4,851,439 A 7/1989 Speiser et al.
4,959,389 A 9/1990 Speiser et al.
5,149,695 A 9/1992 Speiser et al.
5,214,196 A 5/1993 Blank
5,242,905 A 9/1993 Blank
5,359,128 A 10/1994 Blank
5,424,332 A 6/1995 Speiser et al.
5,451,667 A 9/1995 Speiser et al.
5,538,968 A 7/1996 Chiesi et al.
5,548,059 A 8/1996 Bayley et al.
5,972,363 A 10/1999 Klikeman et al.
6,277,882 B1 8/2001 Joshi et al.
6,355,676 B1 3/2002 Joshi et al.
6,359,003 B1 3/2002 Joshi et al.
6,436,992 B1 8/2002 Joshi et al.
6,509,376 B1 1/2003 Joshi et al.
6,812,248 B2 11/2004 Zhang et al.
6,858,750 B2 2/2005 Joshi et al.
7,056,950 B2 6/2006 Rath
7,157,423 B2 1/2007 Joshi et al.
7,279,331 B2 10/2007 Black et al.
7,320,999 B2 1/2008 Joshi et al.
7,364,900 B2 4/2008 Black et al.
7,417,045 B2 8/2008 Anilkumar et al.
7,432,240 B2 10/2008 Joshi et al.
7,612,110 B2 11/2009 Joshi et al.
7,619,001 B2 11/2009 Joshi et al.

OTHER PUBLICATIONS

Thomson Innovation Patent Record, DWPI Accession No. 1979-58797B, English Abs. language Abstract of Japanese Patent Publication No. 54-80439 A, (1979).

(Continued)

Primary Examiner — John Ulm
(74) *Attorney, Agent, or Firm* — Sterne, Kessler, Goldstein & Fox P.L.L.C.

(57) **ABSTRACT**

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.



US008399514B2

(12) **United States Patent**
Lukashev et al.

(10) **Patent No.:** **US 8,399,514 B2**
(45) **Date of Patent:** **Mar. 19, 2013**

(54) **TREATMENT FOR MULTIPLE SCLEROSIS**
(75) Inventors: **Matvey E. Lukashev**, Tewksbury, MA (US); **Gilmore O'Neill**, Medford, MA (US)
(73) Assignee: **Biogen Idec MA Inc.**, Cambridge, MA (US)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
(21) Appl. No.: **13/372,426**

7,803,840 B2 9/2010 Joshi et al.
7,871,977 B2 1/2011 Rischer et al.
7,906,659 B2 3/2011 Joshi et al.
7,915,310 B2 3/2011 Joshi et al.
8,067,467 B2 11/2011 Joshi et al.
2003/0176365 A1 9/2003 Blass
2004/0054001 A1 3/2004 Joshi et al.
2005/0245612 A1 11/2005 Blass
2007/0027076 A1 2/2007 Joshi et al.
2008/0089861 A1 4/2008 Went et al.
2008/0233185 A1 9/2008 Joshi et al.
2010/0130607 A1 5/2010 Gold
2011/0112196 A1 5/2011 Lukashev
2011/0124615 A1 5/2011 Joshi et al.
2011/0293711 A1 12/2011 Joshi et al.
2012/0165404 A1 6/2012 Lukashev

FOREIGN PATENT DOCUMENTS

(22) Filed: **Feb. 13, 2012**
(65) **Prior Publication Data**
US 2012/0196931 A1 Aug. 2, 2012

CA 2248955 A1 5/1997
CN 1125141 A 6/1996
DE 25 30 372 A1 1/1977
DE 26 21 214 A1 11/1977
DE 28 40 498 B1 8/1979
DE 38 34 794 A1 4/1990
DE 197 21 099 A1 11/1998
EP 0 188 749 A2 7/1986
EP 0 312 697 A2 4/1989
EP 0 518 388 A2 12/1992
EP 0 793 966 A1 9/1997
EP 0 852 233 A1 7/1998
GB 2 291 422 A 1/1996
JP 54-80439 A 6/1979
JP 6-345644 A 12/1994
JP 8-99906 A 4/1996
JP 9-221428 A 8/1997
RU 2 189 813 C1 9/2002
WO WO 89/01930 A1 3/1989
WO WO 94/28883 A1 12/1994
WO WO 95/25102 A1 9/1995
WO WO 96/01122 A1 1/1996
WO WO 96/08970 A1 3/1996
WO WO 97/09984 A1 3/1997
WO WO 97/13504 A1 4/1997

Related U.S. Application Data

(63) Continuation of application No. 12/526,296, filed as application No. PCT/US2008/001602 on Feb. 7, 2008, now abandoned.
(60) Provisional application No. 60/888,921, filed on Feb. 8, 2007.
(51) **Int. Cl.**
A61K 31/22 (2006.01)
(52) **U.S. Cl.** **514/549**
(58) **Field of Classification Search** None
See application file for complete search history.

References Cited

U.S. PATENT DOCUMENTS

4,515,974 A 5/1985 Zecher et al.
4,746,668 A 5/1988 Sato et al.
4,851,439 A 7/1989 Speiser et al.
4,959,389 A 9/1990 Speiser et al.
5,149,695 A 9/1992 Speiser et al.
5,214,196 A 5/1993 Blank
5,242,905 A 9/1993 Blank
5,359,128 A 10/1994 Blank
5,424,332 A 6/1995 Speiser et al.
5,451,667 A 9/1995 Speiser et al.
5,538,968 A 7/1996 Chiesi et al.
5,548,059 A 8/1996 Bayley et al.
5,972,363 A 10/1999 Clikeman et al.
6,277,882 B1 8/2001 Joshi et al.
6,355,676 B1 3/2002 Joshi et al.
6,359,003 B1 3/2002 Joshi et al.
6,436,992 B1 8/2002 Joshi et al.
6,509,376 B1 1/2003 Joshi et al.
6,812,248 B2 11/2004 Zhang et al.
6,858,750 B2 2/2005 Joshi et al.
7,056,950 B2 6/2006 Rath
7,157,423 B2 1/2007 Joshi et al.
7,279,331 B2 10/2007 Black et al.
7,320,999 B2 1/2008 Joshi et al.
7,364,900 B2 4/2008 Black et al.
7,417,045 B2 8/2008 Anilkumar et al.
7,432,240 B2 10/2008 Joshi et al.
7,612,110 B2 11/2009 Joshi et al.
7,619,001 B2 11/2009 Joshi et al.

(Continued)

OTHER PUBLICATIONS

Thomson Innovation Patent Record, DWPI Accession No. 1979-58797B, English Abs. language Abstract of Japanese Patent Publication No. 54-80439 A, (1979).

(Continued)

Primary Examiner — John Ulm
(74) *Attorney, Agent, or Firm* — Sterne, Kessler, Goldstein & Fox P.L.L.C.

(57) ABSTRACT

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.

FOREIGN PATENT DOCUMENTS

| | | | |
|----|----------------|----|---------|
| WO | WO 97/44054 | A2 | 11/1997 |
| WO | WO 97/48405 | A1 | 12/1997 |
| WO | WO 98/04290 | A2 | 2/1998 |
| WO | WO 98/27970 | A2 | 7/1998 |
| WO | WO 99/21565 | A1 | 11/1998 |
| WO | WO 01/59072 | A1 | 8/2001 |
| WO | WO 02/02190 | A2 | 1/2002 |
| WO | WO 02/38142 | A2 | 5/2002 |
| WO | WO 02/064129 | A2 | 8/2002 |
| WO | WO 03/020908 | A2 | 3/2003 |
| WO | WO 03/032969 | A2 | 4/2003 |
| WO | WO 2005/023241 | A1 | 3/2005 |
| WO | WO 2005/027899 | A1 | 3/2005 |
| WO | WO 2006/037342 | A2 | 4/2006 |
| WO | WO 2006/050730 | A1 | 5/2006 |
| WO | WO 2006/055871 | A2 | 5/2006 |
| WO | WO 2006/088836 | A2 | 8/2006 |
| WO | WO 2006/088837 | A2 | 8/2006 |
| WO | WO 2006/088840 | A1 | 8/2006 |
| WO | WO 2006/088919 | A2 | 8/2006 |
| WO | WO 2006/088920 | A1 | 8/2006 |
| WO | WO 2006/088921 | A2 | 8/2006 |
| WO | WO 2006/091428 | A2 | 8/2006 |
| WO | WO 2007/005879 | A2 | 1/2007 |
| WO | WO 2007/006307 | A2 | 1/2007 |
| WO | WO 2007/042034 | A1 | 4/2007 |
| WO | WO 2007/042035 | A2 | 4/2007 |
| WO | WO 2008/096271 | A2 | 8/2008 |
| WO | WO 2008/097596 | A2 | 8/2008 |
| WO | WO 2011/100589 | A1 | 8/2011 |

OTHER PUBLICATIONS

English language Abstract of German Patent Publication No. DE 38 34 794 A1, European Patent Office, Espacenet database—Worldwide (2001).

English language Abstract of Japanese Patent Publication No. JP 6-345644 A, European Patent Office, Espacenet database—Worldwide (2001).

English language Abstract of Japanese Patent Publication No. JP 8-99906 A, European Patent Office, Espacenet database—Worldwide (2001).

English language Abstract of Japanese Patent Publication No. JP 9-221428 A, European Patent Office, Espacenet database—Worldwide (2001).

English language Abstract of WIPO Patent Publication No. WO 97/48405 A1, European Patent Office, Espacenet database—Worldwide (2001).

English language Abstract of Russian Patent Publication No. RU 2 189 813 C1, European Patent Office, Espacenet database—Worldwide (2002).

English language Abstract of WIPO Patent Publication No. WO 2005/027899 A1, European Patent Office, Espacenet database—Worldwide (2005).

Altmeyer, P.J., et al., "Antipsoriatic effect of fumaric acid derivatives Results of a multicenter double-blind study in 100 patients," *Journal of the American Academy of Dermatology* 30(6):977-981, American Academy of Dermatology, Inc., United States (1994).

Andersson, M., et al., "Cytokine profile in interferon- β treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood," *Eur. J. Neurol.* 4:567-571, Rapid Science Publishers, England (1997).

Bacharach-Buhles, M., et al., "Fumaric Acid Esters (FAEs) Suppress CD 15- and ODP 4-positive Cells in Psoriasis," *Acta. Derm. Venereol. Suppl.* (Stockh) 186:79-82, Scandinavian University Press, Norway (1994).

Balashov, K.E., et al., "Defective regulation of IFN γ and IL-12 by endogenous IL-10 in progressive MS," *Neurology* 55:192-198, AAN Enterprises, Inc., United States (2000).

Becanovic, K., et al., "Paradoxical effects of arthritis-regulating chromosome 4 regions on myelin oligodendrocyte glycoprotein-induced encephalomyelitis in congenic rats," *Eur. J. Immunol.*

Bettelli, E. and Nicholson, L.B., "The Role of Cytokines in Experimental Autoimmune Encephalomyelitis," *Arch. Immun. Ther. Exp.* 48:389-398, Warszawa, Panstwowy Zaklad Wydawn Lekarskich, Switzerland (2000).

Brown, T.R. and Kraft, G.H., "Multiple Sclerosis: A Paradigm Shift," *Phys. Med Rehabil. Clin. N. Am.* 16:xvii-xx, Elsevier Inc., United States (2005)

Cannella, B., et al., "IL-10 Fails to Abrogate Experimental Autoimmune Encephalomyelitis," *J. Neuroscience Research* 45:735-746, Wiley-Liss, Inc., United States (1996).

Correale, J., et al., "Sulfasalazine aggravates experimental autoimmune encephalomyelitis and causes an increase in the number of autoreactive T cells," *J. Neuroimmunol.* 34:109-120, Elsevier Science Publishers B.V., Netherlands (1991).

Dahlman, I., et al., "Quantitative trait loci disposing for both experimental arthritis and encephalomyelitis in the DA rat; impact on severity of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis and antibody isotype pattern," *Eur. J. Immunol.* 28:2188-2196, Wiley-VCH Verlag GmbH, Germany (1998).

Dal Canto, R.A., et al., "Local Delivery of TNF by Retrovirus-Transduced T Lymphocytes Exacerbates Experimental Autoimmune Encephalomyelitis," *Clinical Immunol.* 90(1):10-14, Academic Press, United States (1999).

De Graaf, K.L., et al., "MHC Class II Isotype- and Allele-Specific Attenuation of Experimental Autoimmune Encephalomyelitis," *J. Immunol.* 173:2792-2802, The American Association of Immunologists, Inc., United States (2004).

De Haan, P., "The Risk of Sensibilization and Contact Urticaria upon Topical Application of Fumaric Acid Derivatives," *Dermatology* 188:126-130, Karger AG, Switzerland (1994).

De Jong, R., et al., "Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate," *Eur. J. Immunol.* 26:2067-2074, Verlag Chemie GmbH, Germany (1996).

Del Prete, G., "The Concept of Type-1 and Type-2 Helper T Cells and Their Cytokines in Humans," *Intern. Rev. Immunol.* 16:427-455, OPA (Overseas Publishers Association) Amsterdam B.V., England (1998).

Dethlefsen, L.A., "Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfumarate on Murine Mammary Carcinoma Cells," *Radiation Res.* 114:215-224, Academic Press, Inc., United States (1988).

Di Marco, R., et al., "Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis," *J. Neuroimmunol.* 116:168-177, Elsevier Science B.V., Netherlands (2001).

Di Rosa, F., et al., "Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis," *Eur. J. Immunol.* 28:3893-3903, Wiley-VCH Verlag GmbH, Germany (1998).

Djerbi, M., et al., "Expression of the Long Form of Human FLIP by Retroviral Gene Transfer of Hemopoietic Stem Cells Exacerbates Experimental Autoimmune Encephalomyelitis," *J. Immunol.* 170:2064-2073, The American Association of Immunologists, Inc., United States (2003).

Dücker, P. and Pfeiff, B., "Zwei Fälle von Nebenwirkungen einer Fumarsäureester—Lokaltherapie," *H+G Zeitschrift für Hautkrankheiten* 65:734-736, Grosse Verlag Berlin, Germany (1990) (Abstract Only in English).

Ferber, I.A., et al., "Mice with a Disrupted IFN- γ Gene Are Susceptible to the Induction of Experimental Autoimmune Encephalomyelitis (EAE)," *J. Immunol.* 156:5-7, The American Association of Immunologists, United States (1996).

Ferrante, P., et al., "Cytokine Production and Surface Marker Expression in Acute and Stable Multiple Sclerosis: Altered IL-12 Production and Augmented Signaling Lymphocytic Activation Molecule (SLAM)-Expressing Lymphocytes in Acute Multiple Sclerosis," *J. Immunol.* 160:1514-1521, The American Association of Immunologists, United States (1998).

Fliegner, L. and Spiegel, P., "Osteomalazie als offenbar seltene

- Furlan, R., et al., "Interferon- β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon- γ and interleukin-4," *J. Neuroimmunol.* 111:86-92, Elsevier Science B.V., Netherlands (2000).
- Galli, G., et al., "Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines," *Eur. J. Immunol.* 30:204-210, Wiley-VCH Verlag GmbH, Germany (2000).
- Gasser, M., et al., "Host Vs Graft and Graft Vs Host Reactions After Allogeneic Heterotopic Small Bowel Transplantation in the Rat," *Transplant. Proc.* 24(3):1128-1129, Appleton & Lange, United States (1992).
- Genain, C.P., et al., "Late Complications of Immune Deviation Therapy in a Nonhuman Primate," *Science* 274:2054-2057, American Association for the Advancement of Science, United States (1996).
- Ghoreschi, K. and Röcken, M., "Immune Deviation Strategies in the Therapy of Psoriasis," *Current Drug Targets—Inflammation & Allergy* 3:193-198, Bentham Science Publishers Ltd., Netherlands (2004).
- Ghoreschi, K., et al., "Fumarates induce a DC2 phenotype in dendritic cells that establishes protective Th2 responses," *Arch. Dermatol. Forschung* 296:420, Springer Verlag, Germany (2005) (Abstract Only).
- Ghoreschi, K., et al., "Fumaric acid ester an antipsoriatic drug abolishes the capacity of T cells to induce Th1-mediated autoimmune disease," *Arch. Dermatol. Res.* 294:28, Springer Verlag, Germany (2002) (Abstract Only).
- Gielen, A.W., et al., "Expression of T cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (TIM-1 and -3) in the rat nervous and immune systems," *J. Neuroimmunol.* 164:93-104, Elsevier B.V., Netherlands (2005).
- Gijbels, K., et al., "Administration of Neutralizing Antibodies to Interleukin-6 (IL-6) Reduces Experimental Autoimmune Encephalomyelitis and is Associated with Elevated Levels of IL-6 Bioactivity in Central Nervous System and Circulation," *Mol. Med J*(7):795-805, Molecular Medicine, United States (1995).
- Giovannoni, G. and Miller, D.H., "Multiple sclerosis and its treatment," *J. R. Coll. Physicians Lond* 33(4):315-322, Royal College of Physicians, England (1999).
- Guggenmos, J., et al., "Antibody Cross-Reactivity between Myelin Oligodendrocyte Glycoprotein and the Milk Protein Butyrophilin in Multiple Sclerosis," *J. Immunol.* 172:661-668, The American Association of Immunologists, Inc., United States (2004).
- Hemmer, B., et al., "Cytokine Phenotype of Human Autoreactive T Cell Clones Specific for the Immunodominant Myelin Basic Protein Peptide (83-99)," *J. Neurosci. Res.* 45:852-862, Wiley-Liss, Inc., United States (1996).
- Hintzen, R.Q. and Polman, C.H., "Th-cell modulation in multiple sclerosis," *Immunol. Today* 18(10):507-508, Elsevier/North-Holland Biomedical Press, England (1997).
- Hohenegger, M., et al., "Nephrotoxicity of Fumaric Acid Monoethyl ester (FA ME)," *Advances in Experimental Medicine and Biology* 252:265-272, Kluwer Academic, United States (1989).
- Hultgren, B., et al., "Genetic Absence of γ -Interferon Delays but Does Not Prevent Diabetes in NOD Mice," *Diabetes* 45:812-817, American Diabetes Association, United States (1996).
- English language excerpt from Hunziker, T. and Schmidli, J., "Is Psoriasis an Autoimmune Disease?" *Therapeutische Umschau* 50:110-113, Dermatologische Klinik der Universität Bern, Switzerland (1993).
- Hunziker, T. and Schmidli, J., "Psoriasis, eine Autoimmunkrankheit?" *Therapeutische Umschau* 50:110-113, Dermatologische Klinik der Universität Bern, Switzerland (1993).
- Issazadeh, S., et al., "Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β ," *J. Neuroimmunol.* 61:205-212, Elsevier Science B.V., Netherlands (1995).
- Issazadeh, S., et al., "Interferon γ , Interleukin 4 and Transforming Nervous System and Lymphoid Cells," *J. Neurosci. Res.* 40:579-590, Wiley-Liss, Inc., United States (1995).
- Issazadeh, S., et al., "Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor- β ," *J. Neuroimmunol.* 69:103-115, Elsevier Science B.V., Netherlands (1996).
- Issazadeh, S., et al., "Major histocompatibility complex-controlled protective influences on experimental autoimmune encephalomyelitis are peptide specific," *Eur. J. Immunol.* 27:1584-1587, VCH Verlagsgesellschaft mbH, Germany (1997).
- Kappos, L., et al., "Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study," *Lancet* 372:1463-1472, Lancet Publishing Group, England (2008).
- Khademi, M., et al., "Induction of systemic TNF α in Natalizumab-treated multiple sclerosis," *Eur. J. Neurol.* 15:309-312, European Federation of Neurological Sciences, England (2008).
- Khademi, M., et al., "Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis," *J. Neuroimmunol.* 103:202-210, Elsevier Science B.V., Netherlands (2000).
- Khademi, M., et al., "T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis," *J. Immunol.* 172:7169-7176, The American Association of Immunologists, Inc., United States (2004).
- Kiehl, R. and Ionescu, G., "A Defective Purine Nucleotide Synthesis Pathway in Psoriatic Patients," *Acta Derm. Venereol. (Stockh)* 72:253-255, Society for the Publication of Acta Dermatovenerologica, Sweden (1992).
- Kjellén, P., et al., "Genetic influence on disease course and cytokine response in relapsing experimental allergic encephalomyelitis," *Int. Immunol.* 10:333-340, Oxford University Press, England (1998).
- Kolbach, D.N. and Nieboer, C., "Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatment," *J. Am. Acad. Derm.* 27(5):769-771, Mosby, United States (1992).
- Krakauer, M., et al., "Dynamic T-lymphocyte Chemokine Receptor Expression Induced by Interferon-beta Therapy in Multiple Sclerosis," *Scand. J. Immunol.* 64:155-163, Blackwell Publishing Ltd., England (2006).
- Krakovski, M. and Owens, T., "Interferon- γ confers resistance to experimental allergic encephalomyelitis," *Eur. J. Immunol.* 26:1641-1646, VCH Verlagsgesellschaft mbH, Germany (1996).
- Kuroda, K., et al., "Fumaric Acid Enhances DNA Synthesis of Rat Hepatocytes by Counteracting the Toxicities of Mitomycin C and Aflatoxin B₁," *Jpn. J. Cancer Res. (Gann)* 77:750-758, Japanese Cancer Association, Japan (1986).
- LaFaille, J.J., et al., "Myelin Basic Protein-specific T Helper 2 (Th2) Cells Cause Experimental Autoimmune Encephalomyelitis in Immunodeficient Hosts Rather than Protect Them from the Disease," *J. Exp. Med.* 186(2):307-312, The Rockefeller University Press, United States (1997).
- LaFaille, J.J., "The Role of Helper T Cell Subsets in Autoimmune Diseases," *Cytokine & Growth Factor Rev.* 9(2):139-151, Elsevier Science Ltd., England (1998).
- Lahti, A. and Maibach, H.I., "Contact urticaria from diethyl fumarate," *Contact Dermatitis* 12:139-140, Munksgaard, Denmark (1985).
- Laman, J.D., et al., "Balancing the Th1/Th2 concept in multiple sclerosis," *Immunol. Today* 19(11):489-490, Elsevier/North-Holland Biomedical Press, England (1998).
- Lehnert, S., et al., "Radiation Response of Drug-Resistant Variants of a Human Breast Cancer Cell Line: The Effect of Glutathione Depletion," *Radiation Res.* 124:208-215, Academic Press, Inc., United States (1990).
- Liedtke, W., et al., "Effective Treatment of Models of Multiple Sclerosis by Matrix Metalloproteinase Inhibitors," *Ann. Neurol.* 44(1):35-46, The American Neurological Association, United States (1998).

- sclerosis and myasthenia gravis," *Neurology* 44:728-734, The American Academy of Neurology, United States (1994).
- Link, J., et al., "Organ-specific Autoantigens Induce Transforming Growth Factor- β mRNA Expression in Mononuclear Cells in Multiple Sclerosis and Myasthenia Gravis," *Annals Neurol.* 35:197-203, The American Neurological Association, United States (1994).
- Link, J., et al., "Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon- γ , interleukin-4 and transforming growth factor- β ," *J. Neuroimmunol.* 49:9-18, Elsevier Science B.V., Netherlands (1994).
- Link, J., et al., "Increased Transforming Growth Factor- β , Interleukin-4, and Interferon- γ in Multiple Sclerosis," *Ann. Neurol.* 36(3):379-386, The American Neurological Association, United States (1994).
- Link, H., "The cytokine storm in multiple sclerosis," *Mult. Scler.* 4:12-15, Stockton Press, England (1998).
- Linker, R.A., et al., "Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies," *Expert Rev. Neurother.* 8(11):1683-1690, Expert Reviews Ltd., England (2008).
- Lobell, A., et al., "Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response," *J. Immunol.* 170:1806-1813, The American Association of Immunologists, Inc., United States (2003).
- Lobell, A., et al., "Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis," *J. Exp. Med.* 187(9):1543-1548, The Rockefeller University Press, United States (1998).
- Lopez, E., et al., "Interferon γ , IL2, IL4, IL10 and TNF α Secretions in Multiple Sclerosis Patients Treated with an Anti-CD4 Monoclonal Antibody," *Autoimmunity* 29:87-92, OPA (Overseas Publishers Association) N.V., England (1999).
- Lorentzen, J.C., et al., "Genetic analysis of inflammation, cytokine mRNA expression and disease course of relapsing experimental autoimmune encephalomyelitis in DA rats," *J. Neuroimmunol.* 80:31-37, Elsevier Science N.V., Netherlands (1997).
- Lorentzen, J.C., et al., "Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant," *J. Neuroimmunol.* 63:193-205, Elsevier Science B.V., Netherlands (1995).
- Lyons, J.-A., et al., "Pathogenesis of acute passive murine encephalomyelitis II. Th1 phenotype of the inducing population is not sufficient to cause disease," *J. Neuroimmunol.* 93:26-36, Elsevier Science B.V., Netherlands (1999).
- Määttä, J.A., et al., "Neutrophils secreting tumor necrosis factor alpha infiltrate the central nervous systems of BALB/c mice with experimental autoimmune encephalomyelitis," *J. Neuroimmunol.* 90:162-175, Elsevier Science B.V., Netherlands (1998).
- Martin, R., et al., "T helper cell differentiation in multiple sclerosis and autoimmunity," *Immunol. Today* 19(11):495-498, Elsevier Science, England (1998).
- Mattner, F., et al., "Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D $_3$," *Eur. J. Immunol.* 30:498-508, Wiley-VCH Verlag GmbH, Germany (2000).
- Matusiewicz, D., et al., "Autoantigen-induced IL-13 mRNA expression is increased in blood mononuclear cells in myasthenia gravis and multiple sclerosis," *Eur. J. Neurol.* 4:468-475, Rapid Science Publisher, England (1997).
- Asadullah, K., et al., "Influence of monomethylfumarate on monocytic cytokine formation—explanation for adverse and therapeutic effects in psoriasis?" *Arch. Dermatol. Res.* 289:623-630, Springer-Verlag, Germany (1997).
- Bacharach-Buhles, M., et al., "The Effect of Fumaric Acid Esters and Dithranol on Acanthosis and Hyperproliferation in *Psoriasis vulgaris*," *Acta Derm. Venereol.* (Stockh) 76:190-193, Scandinavian University Press, Sweden (1996).
- CD40 ligand," *Proc. Natl. Acad. Sci. USA* 94:599-603, The National Academy of Sciences of the United States of America, United States (1997).
- Barcia, C., et al., "Parkinson's Disease and Inflammatory Changes," *Neurotox. Res.* 5(6):411-418, FP Graham Publishing Co., United States (2003).
- Breuer, K., et al., "Therapy of noninfectious granulomatous skin diseases with fumaric acid esters," *Br. J. Dermatol.* 152:1290-1295, British Association of Dermatologists, England (2005).
- Eberlein-König, B., et al., "Disseminated Granuloma Annulare—Treatment with Fumaric Acid Esters," *Dermatology* 210:223-226, S. Karger AG, Switzerland (2005).
- Link, H., et al., "Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis," *J. Neuroimmunol.* 38:63-74, Elsevier Science Publishers B.V., Netherlands (1992).
- Litjens, N.H.R., et al., "Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses," *Eur. J. Immunol.* 34:565-575, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2004).
- Litjens, N.H.R., et al., "Pharmacokinetics of oral fumarates in healthy subjects," *Br. J. Clin. Pharmacol.* 58(4):429-432, Blackwell Publishing Ltd, England (2004).
- Lobell, A., et al., "Presence of CpG DNA and the Local Cytokine Milieu Determine the Efficacy of Suppressive DNA Vaccination in Experimental Autoimmune Encephalomyelitis," *J. Immunol.* 163:4754-4762, The American Association of Immunologists, United States (1999).
- Loewe, R., et al., "Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF- κ B/p65 in Human Endothelial Cells," *J. Immunol.* 168:4781-4787, The American Association of Immunologists, United States (2002).
- Luft, R., "The development of mitochondrial medicine," *Proc. Natl. Acad. Sci. USA* 91:8731-8738, National Academy of Sciences, United States (1994).
- Mayne, M., et al., "Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor- α Expression is Neuroprotective After Intracerebral Hemorrhage," *Stroke* 32:240-248, American Heart Association, Inc., United States (2001).
- McGeer, P.L., et al., "Expression of the histocompatibility glycoprotein HLA-DR in neurological disease," *Acta Neuropathol.* 76:550-557, Springer-Verlag, Germany (1988).
- Muhallab, S., et al., "Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis," *J. Neuroimmunol.* 113:202-211, Elsevier Science B.V., Netherlands (2001).
- Musiek, E.S., et al., "Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration," *J. Neurochem.* 97:1301-1313, International Society for Neurochemistry, England (2006).
- Mustafa, M.I., et al., "T cell immunity and interferon- γ secretion during experimental allergic encephalomyelitis in Lewis rats," *J. Neuroimmunol.* 31:165-177, Elsevier Science Publishers B.V., Netherlands (1991).
- Mustafa, M., et al., "Immunopharmacologic Modulation of Experimental Allergic Encephalomyelitis: Low-Dose Cyclosporin—A Treatment Causes Disease Relapse and Increased Systemic T and B Cell-Mediated Myelin-Directed Autoimmunity," *Scand. J. Immunol.* 38:499-507, Blackwell Scientific Publications, England (1993).
- Mustafa, M., et al., "The major histocompatibility complex influences myelin basic protein 63-88-induced T cell cytokine profile and experimental autoimmune encephalomyelitis," *Eur. J. Immunol.* 23:3089-3095, VCH Verlagsgesellschaft mbH, Germany (1993).
- Mustafa, M., et al., "Protective Influences on Experimental Autoimmune Encephalomyelitis by MHC Class I and Class II Alleles," *J. Immunol.* 153:3337-3344, The American Association of Immunologists, United States (1994).
- Navikas, V., et al., "Increased mRNA Expression of IL-10 in Mononuclear Cells in Multiple Sclerosis and Optic Neuritis," *Scand.*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.